首页> Acta diabetologica> The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

导出原文传递

翻译打印收藏纠错

第一作者： Pantalone KM

作者： Pantalone KM ^[1] ; Kattan MW ; Yu C ; Wells BJ ; Arrigain S ; Jain A ; Atreja A ; Zimmerman RS

作者单位： Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue NA10, Cleveland, OH, 44195, USA. ^[1]

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Acta diabetologica

2009年46卷2期

145-154页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览1

Acta diabetologica

2009年46卷2期

145-154页

检索历史清除

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

Acta diabetologica

相似文献

同项目论文

Acta diabetologica

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

Acta diabetologica

相似文献

同项目论文

Acta diabetologica

相关期刊

检索历史清除